NO314587B1 - HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV - Google Patents
HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV Download PDFInfo
- Publication number
- NO314587B1 NO314587B1 NO20004412A NO20004412A NO314587B1 NO 314587 B1 NO314587 B1 NO 314587B1 NO 20004412 A NO20004412 A NO 20004412A NO 20004412 A NO20004412 A NO 20004412A NO 314587 B1 NO314587 B1 NO 314587B1
- Authority
- NO
- Norway
- Prior art keywords
- xaa
- seq
- ser
- leu
- ile
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 105
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 48
- 239000000427 antigen Substances 0.000 title claims description 32
- 108091007433 antigens Proteins 0.000 title claims description 32
- 102000036639 antigens Human genes 0.000 title claims description 32
- 229960005486 vaccine Drugs 0.000 title claims description 28
- 238000002360 preparation method Methods 0.000 title claims description 22
- 238000000034 method Methods 0.000 title claims description 9
- 238000003018 immunoassay Methods 0.000 title claims description 7
- 230000001105 regulatory effect Effects 0.000 title claims description 5
- 235000001014 amino acid Nutrition 0.000 claims description 40
- 150000001413 amino acids Chemical class 0.000 claims description 39
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 235000018102 proteins Nutrition 0.000 claims description 20
- 239000002671 adjuvant Substances 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 14
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 10
- 150000001408 amides Chemical class 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 230000003308 immunostimulating effect Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 108010028921 Lipopeptides Proteins 0.000 claims description 4
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 4
- 235000013477 citrulline Nutrition 0.000 claims description 4
- 229960002173 citrulline Drugs 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 3
- 239000008223 sterile water Substances 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- JQDFGZKKXBEANU-IMJSIDKUSA-N Ala-Cys Chemical compound C[C@H](N)C(=O)N[C@@H](CS)C(O)=O JQDFGZKKXBEANU-IMJSIDKUSA-N 0.000 claims description 2
- WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 108010087924 alanylproline Proteins 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 101710149951 Protein Tat Proteins 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
- 208000031886 HIV Infections Diseases 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000004949 mass spectrometry Methods 0.000 description 11
- 229920001223 polyethylene glycol Polymers 0.000 description 11
- 238000004989 laser desorption mass spectroscopy Methods 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 208000030507 AIDS Diseases 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 239000006249 magnetic particle Substances 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 108700004025 env Genes Proteins 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 238000006471 dimerization reaction Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 230000001566 pro-viral effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000009572 RNA Polymerase II Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108700004028 nef Genes Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 229940021993 prophylactic vaccine Drugs 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 235000012976 tarts Nutrition 0.000 description 2
- 229940021747 therapeutic vaccine Drugs 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 108091006106 transcriptional activators Proteins 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- OIOAKXPMBIZAHL-LURJTMIESA-N (2s)-2-azaniumyl-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoate Chemical compound CC(C)(C)OC(=O)CC[C@H](N)C(O)=O OIOAKXPMBIZAHL-LURJTMIESA-N 0.000 description 1
- ANAZDOWEOOFEET-UHFFFAOYSA-N (4-hydroxyphenyl) [4-(3-oxo-1h-2-benzofuran-1-yl)phenyl] hydrogen phosphate Chemical compound C1=CC(O)=CC=C1OP(O)(=O)OC1=CC=C(C2C3=CC=CC=C3C(=O)O2)C=C1 ANAZDOWEOOFEET-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-UHFFFAOYSA-N 2-aminohexanoic acid Chemical compound CCCCC(N)C(O)=O LRQKBLKVPFOOQJ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000178270 Canarypox virus Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108091016115 Cyclin-T1 Proteins 0.000 description 1
- 102100024109 Cyclin-T1 Human genes 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710192141 Protein Nef Proteins 0.000 description 1
- 101710150344 Protein Rev Proteins 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108050008861 SH3 domains Proteins 0.000 description 1
- 102000000395 SH3 domains Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- GIAZPLMMQOERPN-YUMQZZPRSA-N Val-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O GIAZPLMMQOERPN-YUMQZZPRSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000002281 colonystimulating effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 108010032806 molgramostim Proteins 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 101150023385 nef gene Proteins 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 108700004030 rev Genes Proteins 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000006656 viral protein synthesis Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/974—Aids related test
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/826—Viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Priority Applications (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20004412A NO314587B1 (no) | 2000-09-04 | 2000-09-04 | HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV |
| CA002421199A CA2421199A1 (en) | 2000-09-04 | 2001-09-03 | Hiv regulatory and auxiliary peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv |
| US10/129,333 US7097971B2 (en) | 2000-09-04 | 2001-09-03 | HIV-1 peptide, antigen, immunogenic composition, diagnostic method and immunoassay kit |
| PCT/NO2001/000363 WO2002020555A2 (en) | 2000-09-04 | 2001-09-03 | Hiv peptides from tat, rev and wef conserved regions and their application as e.g.vaccine components |
| NZ535908A NZ535908A (en) | 2000-09-04 | 2001-09-03 | HIV regulatory and auxilliary peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV |
| HU0303132A HUP0303132A3 (en) | 2000-09-04 | 2001-09-03 | Hiv regulatory and auxiliary peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv |
| CN01815739A CN1458936A (zh) | 2000-09-04 | 2001-09-03 | 来自Tat、Rev和Nef保守区的HIV肽以及它们作为例如疫苗组分的应用 |
| EA200300335A EA006210B1 (ru) | 2000-09-04 | 2001-09-03 | Регуляторные и вспомогательные пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич |
| AT01965768T ATE378350T1 (de) | 2000-09-04 | 2001-09-03 | Hiv-peptide aus tat-, rev- und wef-konservierten regionen und deren anwendung z.b. als impfstoffkomponenten |
| EP01965768A EP1322666B1 (en) | 2000-09-04 | 2001-09-03 | Hiv peptides from tat,rev and wef conserved regions and their application as e.gvacine compnents |
| CN200910140941A CN101628933A (zh) | 2000-09-04 | 2001-09-03 | 来自Tat、Rev和Nef保守区的HIV肽以及它们作为例如疫苗组分的应用 |
| AU8633601A AU8633601A (en) | 2000-09-04 | 2001-09-03 | Hiv regulatory and auxiliary peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv |
| SK401-2003A SK287913B6 (sk) | 2000-09-04 | 2001-09-03 | Peptide derived from HIV-1 regulatory protein, antigens and use thereof, vaccine composition, method of detecting antibodies induced by HIV, immunoassay kit, antibody and plasmid DNA |
| BR0114046-9A BR0114046A (pt) | 2000-09-04 | 2001-09-03 | Peptìdeos reguladores e auxiliares de hiv, antìgenos, composições de vacinas, kit de imunoensaio e um método para detectar anticorpos induzidos por hiv |
| NZ524557A NZ524557A (en) | 2000-09-04 | 2001-09-03 | HIV regulatory and auxiliary peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV |
| ES01965768T ES2296793T3 (es) | 2000-09-04 | 2001-09-03 | Peptidos de vih de regiones conservadas, tat, rev y wef y su aplicacion como por ejemplo componentes de vacuna. |
| JP2002525175A JP2004508382A (ja) | 2000-09-04 | 2001-09-03 | Ｈｉｖ調節及び補助ペプチド、抗原、ワクチン組成物、ｈｉｖにより誘発される抗体を検出するためのイムノアッセイキット及び方法 |
| DE60131432T DE60131432T2 (de) | 2000-09-04 | 2001-09-03 | Hiv-peptide aus tat-, rev- und wef-konservierten regionen und deren anwendung z.b. als impfstoffkomponenten |
| AU2001286336A AU2001286336B2 (en) | 2000-09-04 | 2001-09-03 | HIV peptides from Tat, Rev and Wef conserved and their application as E.G. vaccine components |
| ARP010104195A AR033997A1 (es) | 2000-09-04 | 2001-09-04 | Peptidos regulatorios y auxiliares de vih, antigenos, composiciones de vacunas, kit de inmunoensayo y un metodo para detectar anticuerpos inducidos por vih |
| ZA200301742A ZA200301742B (en) | 2000-09-04 | 2003-03-03 | HIV peptides from tat, rev and nef conserved regions and their application as e.g. vaccine components. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20004412A NO314587B1 (no) | 2000-09-04 | 2000-09-04 | HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20004412D0 NO20004412D0 (no) | 2000-09-04 |
| NO20004412L NO20004412L (no) | 2002-03-05 |
| NO314587B1 true NO314587B1 (no) | 2003-04-14 |
Family
ID=19911532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20004412A NO314587B1 (no) | 2000-09-04 | 2000-09-04 | HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7097971B2 (pt) |
| EP (1) | EP1322666B1 (pt) |
| JP (1) | JP2004508382A (pt) |
| CN (2) | CN101628933A (pt) |
| AR (1) | AR033997A1 (pt) |
| AT (1) | ATE378350T1 (pt) |
| AU (2) | AU8633601A (pt) |
| BR (1) | BR0114046A (pt) |
| CA (1) | CA2421199A1 (pt) |
| DE (1) | DE60131432T2 (pt) |
| EA (1) | EA006210B1 (pt) |
| ES (1) | ES2296793T3 (pt) |
| HU (1) | HUP0303132A3 (pt) |
| NO (1) | NO314587B1 (pt) |
| NZ (2) | NZ524557A (pt) |
| SK (1) | SK287913B6 (pt) |
| WO (1) | WO2002020555A2 (pt) |
| ZA (1) | ZA200301742B (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0108210A (pt) | 2000-02-04 | 2002-10-22 | Univ Duke | Vacina contra o vìrus da imunodeficiência humana |
| ES2573105T3 (es) | 2006-03-10 | 2016-06-06 | Peptcell Limited | Secuencias de péptidos y composiciones |
| JP4931483B2 (ja) * | 2006-06-14 | 2012-05-16 | ルネサスエレクトロニクス株式会社 | 半導体不良解析装置、不良解析方法、及び不良解析プログラム |
| CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| CN102210874A (zh) * | 2011-05-17 | 2011-10-12 | 浙江大学 | 一种hiv重组亚型dna疫苗的制备方法 |
| CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
| EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
| WO2013182661A1 (en) | 2012-06-06 | 2013-12-12 | Bionor Immuno As | Peptides derived from viral proteins for use as immunogens and dosage reactants |
| EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
| CA2894166A1 (en) * | 2012-12-06 | 2014-06-12 | Pin Pharma, Inc. | Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides |
| US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
| EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5219990A (en) * | 1991-01-28 | 1993-06-15 | Biogen, Inc. | Papillomavirus e2 trans-activation repressors |
| WO1994015634A1 (en) | 1992-12-30 | 1994-07-21 | Matthias Rath | Tat and rev oligopeptides in hiv treatment |
| CA2215483C (fr) | 1995-03-08 | 2012-01-03 | Jean-Francois Zagury | Immunogenes denues de toxicite derivant d'une proteine de regulation retrovirale, anticorps, procede de preparation et compositions pharmaceutiques les renfermant |
| US5891994A (en) * | 1997-07-11 | 1999-04-06 | Thymon L.L.C. | Methods and compositions for impairing multiplication of HIV-1 |
| IT1297090B1 (it) * | 1997-12-01 | 1999-08-03 | Barbara Ensoli | Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le |
| FR2773156B1 (fr) | 1997-12-26 | 2000-03-31 | Biovacs Inc | Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida |
| NO311807B1 (no) * | 1999-03-04 | 2002-01-28 | Bionor Immuno As | HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV |
| WO2000078969A1 (en) * | 1999-06-21 | 2000-12-28 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv tat peptides and multiple peptide conjugate system |
| SE514629C2 (sv) * | 2000-04-12 | 2001-03-26 | Kjell Sjoegren | Smådjurstoalett |
-
2000
- 2000-09-04 NO NO20004412A patent/NO314587B1/no not_active IP Right Cessation
-
2001
- 2001-09-03 CN CN200910140941A patent/CN101628933A/zh active Pending
- 2001-09-03 ES ES01965768T patent/ES2296793T3/es not_active Expired - Lifetime
- 2001-09-03 NZ NZ524557A patent/NZ524557A/en not_active IP Right Cessation
- 2001-09-03 DE DE60131432T patent/DE60131432T2/de not_active Expired - Lifetime
- 2001-09-03 CA CA002421199A patent/CA2421199A1/en not_active Abandoned
- 2001-09-03 NZ NZ535908A patent/NZ535908A/xx not_active IP Right Cessation
- 2001-09-03 CN CN01815739A patent/CN1458936A/zh active Pending
- 2001-09-03 JP JP2002525175A patent/JP2004508382A/ja active Pending
- 2001-09-03 HU HU0303132A patent/HUP0303132A3/hu unknown
- 2001-09-03 WO PCT/NO2001/000363 patent/WO2002020555A2/en active IP Right Grant
- 2001-09-03 SK SK401-2003A patent/SK287913B6/sk not_active IP Right Cessation
- 2001-09-03 BR BR0114046-9A patent/BR0114046A/pt not_active IP Right Cessation
- 2001-09-03 AT AT01965768T patent/ATE378350T1/de not_active IP Right Cessation
- 2001-09-03 EA EA200300335A patent/EA006210B1/ru not_active IP Right Cessation
- 2001-09-03 EP EP01965768A patent/EP1322666B1/en not_active Expired - Lifetime
- 2001-09-03 AU AU8633601A patent/AU8633601A/xx active Pending
- 2001-09-03 US US10/129,333 patent/US7097971B2/en not_active Expired - Fee Related
- 2001-09-03 AU AU2001286336A patent/AU2001286336B2/en not_active Ceased
- 2001-09-04 AR ARP010104195A patent/AR033997A1/es active IP Right Grant
-
2003
- 2003-03-03 ZA ZA200301742A patent/ZA200301742B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004508382A (ja) | 2004-03-18 |
| US20050053616A1 (en) | 2005-03-10 |
| ATE378350T1 (de) | 2007-11-15 |
| CN101628933A (zh) | 2010-01-20 |
| WO2002020555A3 (en) | 2002-06-06 |
| CN1458936A (zh) | 2003-11-26 |
| CA2421199A1 (en) | 2002-03-14 |
| WO2002020555A2 (en) | 2002-03-14 |
| ZA200301742B (en) | 2004-06-21 |
| SK287913B6 (sk) | 2012-03-02 |
| BR0114046A (pt) | 2003-07-22 |
| DE60131432D1 (de) | 2007-12-27 |
| AU2001286336B2 (en) | 2007-03-15 |
| EA200300335A1 (ru) | 2003-08-28 |
| EA006210B1 (ru) | 2005-10-27 |
| NO20004412L (no) | 2002-03-05 |
| US7097971B2 (en) | 2006-08-29 |
| HUP0303132A2 (hu) | 2005-03-29 |
| ES2296793T3 (es) | 2008-05-01 |
| SK4012003A3 (en) | 2003-09-11 |
| DE60131432T2 (de) | 2008-09-18 |
| AR033997A1 (es) | 2004-01-21 |
| EP1322666A2 (en) | 2003-07-02 |
| NO20004412D0 (no) | 2000-09-04 |
| NZ524557A (en) | 2005-04-29 |
| HUP0303132A3 (en) | 2012-09-28 |
| EP1322666B1 (en) | 2007-11-14 |
| AU8633601A (en) | 2002-03-22 |
| NZ535908A (en) | 2006-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5814331B2 (ja) | Ｈｉｖペプチド、抗原、ワクチン組成物、免疫学的検定キット及びｈｉｖによって誘発された抗体を検出する方法 | |
| US7612168B2 (en) | Modified HIV peptides, antigens, compositions, immunoassay kit and a method of detecting antibodies induced by HIV | |
| AU2001282706A1 (en) | HIV peptides from conserved in gag p17 and 924 and their application in E.G. vaccines | |
| NO314587B1 (no) | HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV | |
| AU2001286336A1 (en) | HIV peptides from Tat, Rev and Wef conserved and their application as E.G. vaccine components | |
| AU2004200155C1 (en) | HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |